Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.
about
Oncogenes: The Passport for Viral Oncolysis Through PKR InhibitionTyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsThird-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerUpdate on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitorsEfficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFRThird-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerAZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung CancerWhacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancerDrug Resistance to EGFR Inhibitors in Lung CancerTumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapyCharacterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.The pharmacogenomics of drug resistance to protein kinase inhibitors.Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First LineInhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma.Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy.Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.Extinction rates in tumour public goods gamesA novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR.The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells.Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.Understanding and targeting resistance mechanisms in NSCLC.Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.
P2860
Q26739777-A37E6DB2-8F42-4F35-91A7-4E4F48514743Q26741318-D8DA845B-01C4-4541-A2E5-47C8E1B2EFFBQ26748851-F3A0686B-6F5E-4B35-95D5-068CEBF51894Q28069708-89C0CC0D-DC9B-4450-AFB8-83AD3D6E31FBQ33618558-1B5A5710-53A0-474D-8AFF-9595536C1D9AQ33740707-10CE63E2-63EC-496F-AAB0-1EE69A657607Q34497467-84F3884D-8A27-4662-B0F6-A40A31F99228Q34550460-74A57BB8-EAF3-4AD4-B1FA-AEE7D586CCC3Q35844624-BBC21D2B-A20C-4E66-B797-046095017B3CQ36427381-CF638F0E-C8C0-4F85-8EA7-DA9786C306CFQ36605057-D24539F4-3ECA-4A07-A7EB-D3C57572AF20Q36775204-4CC573B2-8706-4D9F-863B-A65FCD115A37Q36801144-D4F3084B-1796-494C-B375-E542606F45A5Q36834883-5928938E-144B-4E2B-A062-25B20516A2B3Q36989342-C29ECD7D-62B4-41A0-9B01-55E252FB3E42Q37000646-201C0A30-5DDE-4FEE-BD1A-26C0E1A9FCADQ37085219-37575EEB-9AE7-4E17-8984-D0C0FE2F6512Q37412555-A5958A1E-68BB-468C-8872-656734AAF767Q37726138-ED5A41A6-E67B-4A88-A346-DD579E396B83Q38598893-D9AB13BC-9A40-4A28-B9E4-250369026033Q38731759-F356D615-8CD9-450E-9186-7CAE735C22BDQ38740315-AC43F6E9-563C-402E-9038-8D1FCE9CC41BQ38745430-76F5517E-FA95-4BAB-B6E0-785EC30D5E3EQ38790929-74EF7131-7AF6-46E0-B24C-9A4A0E372A16Q38833666-B6462F82-7858-46AE-B226-340A1CBCE5BBQ38952751-D7697352-E3EA-4D92-A3D6-A4C76C3D57BAQ38991958-154802B1-B398-480D-B831-59070E9F1438Q39023478-DC765B84-B050-44FD-B5FD-F82FC78A2622Q39114552-B5D5055E-6493-4B86-AC76-DCFE628E922CQ39176363-2114F588-2F25-4997-A9BA-0B681555D846Q39255218-2EFA5153-E0CE-4018-9D25-C9A34B563C8BQ39288360-D2F89B6E-F095-402E-8670-90D1BF975156Q41911703-5DB8F974-9C52-42A5-A4F8-EDAB81599981Q42262863-E1D181F9-95C6-4A66-990E-5817EA78859FQ42367902-C4505FE3-E3A6-498B-9C28-BD4ACFC06856Q42378470-240ECC6B-9F7F-4FA7-9CE8-71F5AFE4B3E7Q45983599-456D6141-112C-4F54-9C5B-B068B00DB9FFQ46915997-2D1B4F97-9C5C-4FAB-83A1-3819B38E034AQ47095218-2041ADD1-673B-4EB2-A605-20858B2D6BC6Q47146662-C425128A-F68A-4641-A9B1-73F2F6968010
P2860
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Acquired Resistance to the Mut ...... gnaling in Preclinical Models.
@en
type
label
Acquired Resistance to the Mut ...... gnaling in Preclinical Models.
@en
prefLabel
Acquired Resistance to the Mut ...... gnaling in Preclinical Models.
@en
P2093
P2860
P1433
P1476
Acquired Resistance to the Mut ...... gnaling in Preclinical Models.
@en
P2093
Aleksandra A Markovets
Ambar Ahmed
Brian Dougherty
Catherine A Eberlein
Catherine B Meador
Claire H Barnes
Daniel Stetson
Darren A E Cross
Eiki Ichihara
Elizabeth L Christey O'Brien
P2860
P304
P356
10.1158/0008-5472.CAN-14-3167
P407
P50
P577
2015-04-13T00:00:00Z